Blog Detail

CPD: Brivaracetam

Post Title

CPD: Brivaracetam

An analogue of levetiracetam has recently been licensed as adjunctive therapy for partial-onset seizures in patients with or without secondary generalisation. The drug, called brivaracetam, binds to synaptic vesicle protein 2A (SV2A) which is known to modulate neurotransmitter release.

Several studies have demonstrated that brivaracetam has a much higher potency and efficacy than levetiracetam as an anti-seizure and anti-epileptogenic agent and is associated with significantly reduced seizure frequency. Additionally, it is generally well-tolerated with the most common side effects being somnolence and dizziness which are generally mild to moderate in severity.

Comments (0)

Leave a Comment